BIOMAT Database Logo BIOMAT Database Logo

Miliary pulmonary granulomas induced by the methanol extraction residue of BCG (MER/BCG) in patients with melanoma. 1982

A H Bartal, and O Adler, and Y Cohen, and E Robinson

UI MeSH Term Description Entries
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006099 Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents. Granulomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001500 BCG Vaccine An active immunizing agent and a viable avirulent attenuated strain of MYCOBACTERIUM BOVIS, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. Bacillus Calmette Guerin Vaccine,Calmette Guerin Bacillus Vaccine,Calmette's Vaccine,Calmette Vaccine,Calmettes Vaccine,Vaccine, BCG,Vaccine, Calmette's

Related Publications

A H Bartal, and O Adler, and Y Cohen, and E Robinson
Evaluation of therapy with methanol extraction residue of BCG (MER).
January 1982, Cancer immunology, immunotherapy : CII,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Enhancement of Schistosoma mansoni infection induced by the methanol-extraction residue (MER) fraction of BCG.
March 1981, Journal of helminthology,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Characterization of methanol extraction residue (MER) from Bacillus Calmette-Guérin (BCG).
October 1979, The Journal of antibiotics,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
December 1973, National Cancer Institute monograph,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER).
October 1982, Cancer,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients.
July 1975, British journal of cancer,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Pulmonary abnormalities in patients intravenously receiving the methanol extraction residue (MER) of Bacillus Calmette-Guerin.
March 1980, Cancer,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Oral administration of the methanol extraction residue of BCG (MER/BCG): a phase I study in non-oat cell lung cancer patients.
January 1983, International journal of immunopharmacology,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Vitiligo associated with BCG-methanol extraction residue in malignant melanoma. Report of a case.
January 1979, Dermatologica,
A H Bartal, and O Adler, and Y Cohen, and E Robinson
Pulmonary granulomas induced by BCG.
June 1978, Cancer,
Copied contents to your clipboard!